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During the eighties and nineties there was 
much debate and controversy about the e ects of 
ovarian hormones on muscle strength in females1-5. 
Researchers used various models of reproductive 
functioning to investigate this relationship including; 
the menstrual cycle6, the menopause7, in vitro 
fertilisation (IVF) treatment8, pregnancy9, oral 
contraceptives10 (OC’s) and hormone replacement 
therapies11 (HRT’s). Since then, numerous review 
papers12-14 have been published, yet the number of 
original research outputs has declined. To date, there 
is still no consensus regarding the role of oestrogen in 
force production or universal guidelines for advising 
females about reproductive status and skeletal muscle 
function.  is review will consider data from the 
last ten years examining the relationship between 
oestrogen and muscle strength. It is important to 
study this relationship as the female hormonal milieu 
changes across the lifespan and muscle strength 
is an enabling factor which facilitates functional 
independence and athletic performance. 
Interestingly, the association between sex hormones 
and the muscular system was  rst noted almost 100 
years before the majority of research in this  eld was 
conducted: Jacobi15 observed periodic changes in 
muscle strength during the menstrual cycle. Since 
then, several authors have linked cyclical changes 
in muscle strength, in eumenorrheic females, with 
 uctuations in ovarian hormone levels across the 
menstrual cycle3,4,10,16-17. However, there is also 
substantial evidence to the contrary1,5,18-20. During 
the same period, numerous authors have reported 
a notable reduction in strength at the onset on the 
menopause that can be preserved by HRT11,21-23. In 
contrast, a similar number of reports have contradicted 
this evidence and have shown no relationship2,7,24-25. 
 e in uence of OC’s on muscle function is also 
confusing with some authors16,26 suggesting an 
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e ect and others showing no di erence4,10. For a 
comprehensive review of the literature published 
between 1980 and 2000 see Cable and Elliott12. 
Data from this era was impaired by a variety of 
design issues such as; inconsistent terminologies (e.g. 
menstrual cycle phase and postmenopausal status), 
inaccurate methods (e.g. basal body temperature 
assessment to confirm ovulation), subjective 
measures (e.g. retrospective questionnaires to 
establish menstrual cycle phase), grouping non-
homogenous participants (e.g. using OC and 
The evidence for an effect of oestrogen on muscle strength
HRT users on different brands and types of 
exogenous steroid supplementation) and comparing 
incompatible strength measures (e.g. different 
test modalities and muscle types). For a detailed 
summary of these and other issues see Cable and 
Elliott12, Elliott-Sale et al.27 and Elliott-
Sale and Martin28. ! e purpose of this current 
perspective is to summarise the research published 
since 2004 and to critically evaluate if the research 
from the eighties and nineties has in" uenced and 
informed the research design of recent studies. 
During the last ten years approximately 15 papers 
have shown an e ect of oestrogen on muscle strength 
or determinants of muscle strength (TABLE 1). 
! ree studies used the menstrual cycle as a model 
of reproductive functioning29, while two further 
studies combined the menstrual cycle with OC 
use32-33. One report examined the effects of OC 
consumption and withdrawal on strength34 and one 
combined previous OC use with a control group 
that had never used OC’s35. Undoubtedly, the most 
common reproductive functioning models used in 
the literature in the last decade were the menopause 
and HRT36-44. ! ese models were used to investigate 
numerous facets of muscle strength including; muscle 
sti ness30 and soreness29, dynamic and isometric force 
production38,43, power41, endurance32, performance33, 
functional capacity39 and gene expression37. Generally, 
the relationship between oestrogen and muscle strength 
was positive; high concentrations of oestradiol were 
associated with the preservation of muscle strength 
and mass in addition to mobility and function36-44. 
However, one study showed a negative relationship 
between oestrogen concentrations and muscle 
function; Allali et al.35 showed increased performance 
in a number of functional tests in previous OC users. 
Only one study showed a detrimental e ect of high 
concentrations of oestrogen on muscle function; 
Nicolay et al.32 found that static handgrip endurance 
was reduced in the late-follicular phase of the menstrual 
cycle when oestrogen levels are high.
TABLE 1 - Studies showing an effect of oestrogen on muscle strength or determinants of muscle strength.
Authors Reproductive status Strength tests Conclusions
Bell et al.30 Eumenorrheic females 
(3-5 days after the onset 
of menses) & men.
Hamstring neuromechanical 
variables; hamstring 
musculotendinous sti ness, 
rate of force production, 
time to 50% peak torque, & 
electromechanical delay
Correlations exist between muscle 
properties & reproductive hormones. 
Females, however, may be more sensitive 
to reproductive hormones & their 
" uctuations.
Dieli-Conwright 
et al.44
Post-menopausal; HRT & 
non-HRT users.
10 sets of 10 maximal 
eccentric repetitions of 
single-leg extension on a 
dynamometer.
Data suggest that postmenopausal 
women using HRT express greater 
myostatin-related gene expression, which 
may re" ect a mechanism by which 
oestrogen in" uences the preservation of 
muscle mass. Further, postmenopausal 
women using HRT experienced a 
profoundly greater myostatin-related 
response to maximal eccentric exercise.
continue
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TABLE 1 - Studies showing an effect of oestrogen on muscle strength or determinants of muscle strength 
(continuation).
Authors Reproductive status Strength tests Conclusions
Sakamaki et al.31 Eumenorrheic females 
(follicular [FP] & luteal 
phase [LP]) & men.
MRI-measured biceps 
muscle volume (MV) & 
isometric elbow  exion 
strength.
Results indicate that muscle hypertrophy 
& strength gain are higher in the LP 
than in the FP following 6 days of blood 
 ow restriction training, although the 
sex di erence in the training response is 
non-existent.
Bryant et al.33 Monophasic OC pill 
users and eumenorrheic 
females.
Leg sti ness and foot centre 
of pressure during hopping.
Consistent lower limb dynamics 
of monophasic OC users demands 
less reliance on acutely modi ed 
neuromuscular control strategies during 
dynamic tasks and may explain the 
lower rate of lower limb musculoskeletal 
injuries in this population compared 
with non-OC users.
Finni et al.43 Post-menopausal 
monozygotic twin pairs 
discordant for HRT.
Maximal voluntary torque & 
twitch characteristics using 
electrical stimulation before 
& after intermittent dynamic 
plantar exor exercise until 
exhaustion.
In early postmenopausal women, 
involuntary but not voluntary 
force-generating mechanisms of the 
plantar exors are augmented by the use 
of HRT.
Allali et al.35 Pre & post-menopausal; 
who were either (1) 
previous OC’s users or (2) 
never used OC’s. 
Timed get-up-and-go test, 
 ve-times-sit-to-stand test & 
8-feet speed walk.
OC past users had signi cantly greater 
performance, on three strength-related 
tests than the never used group.
Dieli-Conwright 
et al.40
Post-menopausal; HRT & 
non-HRT users.
10 sets of 10 maximal 
eccentric repetitions of 
single-leg extension on a 
dynamometer at 60 degrees 
/s with 20-s rest periods 
between sets.
Postmenopausal women not using HRT 
experienced greater muscle damage after 
maximal eccentric exercise, indicating a 
possible protective e ect of HRT against 
exercise-induced skeletal muscle damage.
Rechichi & 
Dawson34
 ree time points of a 
single OC cycle; during 
consumption phase, early 
& late withdrawal phase.
Drop jumps (30cm and 
45cm heights), a counter 
movement jump, a 10s cycle 
sprint test & a 5x 6s repeated 
sprint cycle test.
Reactive strength varied signi cantly 
throughout an OC cycle, possibly 
due to the action of hormones on 
neuromuscular timing & the stretch-
shortening cycle.
Ronkainen et al.41 Post-menopausal 
monozygotic female twin 
pairs discordant for HRT.
Habitual & maximal 
walking speeds over 10 m, 
thigh muscle composition, 
lower body muscle power 
assessed as vertical jumping 
height, and maximal 
isometric hand grip and knee 
extension strength.
Long-term HRT was associated with 
better mobility, greater muscle power, & 
favourable body & muscle composition 
among 54- to 62-yr-old women. HRT 
is a potential agent in preventing muscle 
weakness & mobility limitation in older 
women.
Van Geel et al.42 Post-menopausal. Maximum quadriceps 
extension strength (MES) 
& maximum handgrip 
strength, timed up-and-go 
test.
Age-related loss of MES in 
postmenopausal women is partly 
dependent on the presence of 
endogenous bioavailable testosterone and 
oestrogen.
continue
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TABLE 1 - Studies showing an effect of oestrogen on muscle strength or determinants of muscle strength 
(continuation).
Authors Reproductive status Strength tests Conclusions
Nicolay et al.32 Eumenorrheic & OC 
users; tested early-
follicular (day 4-6), late-
follicular (day 11-13), & 
luteal (day 20-23) phases 
of the menstrual cycle. 
Male control participants 
also.
Grip strength; single 
repetition maximum 
voluntary contraction, 
20-repetition grip test, & a 
30-s static (continual) hold.
Menstrual cycle phase did not have 
a detectable e ect on any measure of 
strength (absolute force production) in 
eumenorrheic women or women taking 
chemical contraceptives. However, 
static endurance (percent change in 
force throughout the 30-s hold) was 
signi cantly reduced during the late-
follicular phase in the eumenorrheic 
women, when levels of oestrogen are 
expected to be elevated.  e women 
using OC’s did not experience any 
similar  uctuation in static endurance 
across the three phases; however the 
static endurance of the contraceptive 
group was signi cantly lower than the 
eumenorrheic women during both the 
early-follicular and luteal phases.
Pollanen et al.37 Post-menopausal; HRT & 
non-HRT users.
Explorative microarray 
experiment to characterize 
possible e ects of 
continuous, combined HRT 
& oestrogen deprivation on 
skeletal muscle.
During the early postmenopausal 
years, when there is no counteracting 
medication available, muscle 
transcriptome changes notably, whereas 
HRT appears to slow down this 
phenomenon & could therefore aid 
in maintaining proper muscle mass & 
function after menopause.
Rolland et al.38 Post-menopausal. Percentage of loss per year 
of isometric knee extensor 
strength.
Loss of muscle strength was positively 
correlated with oestrone (r = 0.29) and 
was signi cantly predicted by oestrone 
(0.32; 6%). 
Sowers et al.39 Midlife women. 2-lb lift, sit-to-stand, timed 
stair climb, timed walk, 
velocity & hand grip.
Hysterectomy, even with availability of 
an oestrogen source, seems to be a "risk" 
state for diminishing physical function at 
midlife, & this may initiate a vulnerable 
stage for future compromised quality of life.
Kerksick et al.29 Men & women 
(eumenorrheic; midluteal 
phase of menstrual cycle).
Knee extensor strength & 
soreness.
Strength changes were similar among 
genders, however in females 17beta-
oestradiol provided some protection 
against muscle injury, oxidative stress, & 
apoptosis. Di erences between genders 
may provide greater endogenous protection 
against oxidative stress and apoptosis.
Onambele et al.36 Pre-menopausal, post-
menopausal with HRT 
use & post-menopausal 
without HRT use.
Size, strength, voluntary 
activation capacity & index 
of crossbridge force state in 
the thumb adductor muscles.
 e presence, rather than absence of 
oestrogen, is associated with relatively 
higher muscle function, which limits the 
potential for any further training-induced 
increments in muscle performance.  ey 
proposed that this would be expected 
if the muscle strengthening actions of 
training and oestrogen share a common, 
partially saturable physiological pathway. 
Furthermore they suggested that the 
mechanism that is involved in the early 
training-induced strength increment cannot 
be due to increased size or recruitment & 
would appear instead to be due to increased 
motor unit  ring frequency.
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The evidence against an effect of oestrogen on muscle strength
TABLE 2 - Studies showing no effect of oestrogen on muscle strength or determinants of muscle strength.
Since 2004, approximately 20 studies have not 
shown any relationship between oestrogen and 
muscle strength (TABLE 2). Of these studies, nine 
employed a menopause model with and without 
HRT45-53, while six used the menstrual cycle54-60. One 
study used a pubertal model59 and the remaining 
studies used OC’s61-63. Muscle function was 
assessed through a variety of measures including; 
maximal dynamic53 and isometric58 strength, 
endurance46, performance60, power45 and functional 
capacity48. Despite signi cant changes in oestrogen 
concentration, none of these studies were able 
to demonstrate the putative role of oestrogen in 
determining muscle strength.
Authors Reproductive status Strength tests Conclusions
CHOQUETTE et al.53 Overweight-to-obese 
post-menopausal women; 
divided into 4 groups: (1) 
placebo, (2) iso! avones, 
(3) exercise & placebo & 
(4) exercise & iso! avone.
Maximal muscle strength at 
the leg press & the bench 
press, muscle mass index, 
muscle quality in the legs & 
relative strength.
Iso! avones, irrespective of exercise, did 
not produce changes in any strength 
related variables.
Ekenros et al.63 Same woman at 3 speci c 
phases of an OC cycle, as 
well as during a menstrual 
cycle of the corresponding 
cycle days (non-OC cycle).
Maximal isokinetic muscle 
strength of knee extensors, 
isometric handgrip strength, 
& 1-leg hop test for distance.
No support for any signi cant in! uence 
of OC use on muscle strength & hop 
performance in healthy moderately active 
women.
Wild et al.59 Pubertal girls, in Tanner 
stage II & 4-6 months from 
their peak height velocity. 
Tested 4 times during the 
12 months of their growth 
spurt, according to the 
timing of their maturity 
o= set (test 1: maturity o= set 
= -6 to -4 months; test 2: 
maturity o= set = 0 months; 
test 3: maturity o= set = +4 
months; test 4: maturity 
o= set = +8 months).
Anterior knee laxity, lower 
limb ! exibility, & isokinetic 
strength.
A signi cant e= ect of time on anterior 
knee laxity was shown from the time 
of peak height velocity, although no 
changes in oestradiol concentration 
were displayed over time. Participants 
displayed a signi cant increase in 
isokinetic quadriceps strength over time, 
with no apparent increase in isokinetic 
hamstring strength.
Jacobsen et al.52 Women aged >70 were 
randomized; 290 received 
the allocated intervention: 
97 placebo, 101 
raloxifene, & 92 tibolone.
Handgrip strength. In women >70 years old, raloxifene 
and tibolone signi cantly & similarly 
increased body mass density but not 
muscle strength. 
Ribom et al.51 Post-menopausal. Y e stand-up test was used 
to assess leg muscle strength 
& balance. Handgrip & 
leg muscle strength were 
measured using JAMAR & 
modi ed
Cybex dynamometers.
Short-term treatment with low-dose 
tibolone (1.25 mg/d) seems not to a= ect 
muscle strength in older women.
Burgess et al.57 Eumenorrheic; days 3 +/- 
0.4, 13 +/- 0.2, and 21 
+/- 0.3.
In vivo patellar tendon 
properties assessed by 
dynamometry.
In terms of tendon properties, menstrual 
cycle phase does not necessarily need to 
be considered when organizing training 
and competition schedules.
continue
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Authors Reproductive status Strength tests Conclusions
Montgomery & 
Shultz58
Eumenorrheic; early 
follicular and either the 
early luteal or midluteal 
phases.
Maximal voluntary isometric 
contraction (MVIC) torque 
of the knee  exors and 
extensors.
 igh MVIC torque did not change 
from time of menses (when oestradiol 
& progesterone were lowest) to time 
in the luteal phase after an unopposed 
oestradiol rise or combined oestradiol & 
progesterone rise.
Tsampoukos et al.60  ree phases of the 
menstrual cycle; follicular, 
just prior to ovulation & 
luteal.
Repeated 30-s sprint on a 
non-motorised treadmill 
interspersed with a 2-min 
rest, peak power output & 
mean power output.
Hormonal  uctuations due to menstrual 
cycle phase do not interfere with 
maximal intensity whole body sprinting 
& the metabolic responses to such 
exercise.
Nichols et al.62 Premenopausal; OC & 
non-OC users.
One-repetition maximum 
bench press, 10-repetition 
maximum leg extension, 
isokinetic peak torque bench 
press, & isokinetic peak 
torque leg extension.
 e use of combination OCAs did not 
provide su  cient androgenic e ect 
to increase strength gains beyond the 
stimulus of the training protocol.
Abt et al.56 Pre-menopausal; 
eumenorrheic (menses, 
post-ovulatory, & 
mid-luteal phases of the 
menstrual cycle).
Fine motor coordination, 
postural stability, knee 
strength, & knee joint 
kinematics and kinetics.
Neuromuscular & biomechanical 
characteristics are not in uenced 
by  uctuation in oestradiol and 
progesterone. All neuromuscular & 
biomechanical characteristics remained 
invariable between testing sessions 
despite concentration changes in 
oestradiol and progesterone.
Hertel et al.55 Eumenorrheic; mid-
follicular, ovulatory, & 
mid-luteal stages.
Knee  exion & extension 
peak torque, passive knee joint 
position sense, & postural 
control in single leg stance.
Neuromuscular control & knee joint 
laxity do not change substantially across 
the menstrual cycle of females despite 
varying oestrogen & progesterone levels.
Lebrun et al.49 Women aged 56-
73 years, 8-30 years 
postmenopausal.
Muscle strength 
was measured using 
dynamometry.
No consistent relation was found between 
serum levels of hormones measured 
& strength. In the elderly & late 
postmenopausal women hormonal factors 
do not predict quality of life.
Sipila et al.50 Post-menopausal women. Isometric muscle strength. Higher serum oestradiol concentration 
& greater muscle strength were 
independently associated with a low 
incidence of fall-related limb fractures 
even after adjustment for bone density. 
Hormonal status & muscle strength 
have their own separate mechanisms 
protecting from fall-related fractures.
Dayal et al.46 Postmenopausal women 
randomized to (1) 
hydroepiandrostenedione 
(DHEA) 50 mg daily, 
(2) conjugated equine 
oestrogen (CEE) 0.625 
mg daily, (3) DHEA 50 
mg+CEE 0.625 mg daily, 
or (4) placebo.
Muscle mass, muscle 
strength & muscle 
endurance.
Compared with no hormone therapy, 
none of the supplemental hormone 
groups caused signi cant changes in 
muscle mass, muscle strength & muscle 
endurance. Androgen replacement 
therapy, with DHEA, to menopausal 
women increases serum androgen levels 
without any appreciable e ect on muscle 
cross-sectional area, muscle strength, 
muscle function, or improvement in 
health-related QOL.
TABLE 2 - Studies showing no effect of oestrogen on muscle strength or determinants of muscle strength 
(continuation).
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Methodological issues and advancements
 e menopause and the menstrual cycle remain 
the most popular models for investigating the e ects 
of oestrogen on muscle strength; accounting for more 
than two thirds of recent publications. Surprisingly, the 
IVF model has not been used 2004, despite providing 
acute supra-physiological changes in oestradiol 
concentration without the confounding factors 
associated with the menopause and the menstrual 
cycle: notably age and inter and intra-individual 
variability in hormone secretion. In addition, both 
puberty and pregnancy have been under-utilised, 
even though they provide substantial chronic natural 
changes in the female hormonal milieu9.
It is encouraging to note that the majority of 
recent studies have used blood samples to con rm 
reproductive status; post-menopausal38,50, menstrual 
cycle phase29-30 and OC use9,34. However, no 
studies have speci cally measured the bioavailable 
concentration of oestradiol, which may be of particular 
interest for studies using post-menopausal groups; 
previous work has shown that the bioavailability of 
oestradiol did not signi cantly di er between two 
phases of the menstrual cycle64.  e bioavailable 
part of oestrogen is not a set proportion of the total 
concentration and is dependent on its a  nity to 
and concentration of its binding protein.  erefore, 
models of reproductive functioning, such as the 
menopause, might influence the bioavailable 
concentration of oestradiol and subsequently its 
relationship with muscle strength. Moreover, there are 
TABLE 2 - Studies showing no effect of oestrogen on muscle strength or determinants of muscle strength 
(continuation).
Authors Reproductive status Strength tests Conclusions
Elliott et al.61 Pre-menopausal; OC & 
non-OC users (days 7 & 
14 of pill consumption & 
day 5 of pill withdrawal 
& days 2 & 21 of the 
menstrual cycle).
Maximum dynamic & 
isometric leg strength & 
maximum isometric strength 
of the  rst dorsal interosseus 
muscle.
Oral contraceptive use does not 
signi cantly a ect muscle strength. 
Moreover, oral contraceptive users 
are not stronger or weaker than their 
eumenorrheic counterparts.
Grundberg et al.54 Pre-menopausal. Quadriceps, hamstring & 
grip strength.
 e TA-repeat in the human ERalpha gene 
does not correlate with muscle strength or 
body mass measurements, indicating that 
body composition is not as sensitive to 
genetic variation in this receptor as other 
target organs for oestrogen.
Schaap et al.47 Men & women aged 65-
88 years.
Physical performance, 
functional limitations & 
muscle strength.
Low levels of sex hormones were 
associated with impaired mobility and 
low muscle strength in men, but not in 
women. Levels of sex hormones were 
not associated with the incidence of falls 
neither in men, nor in women.
Taaffe et al.48 Post-menopausal; current 
estrogen replacement 
therapy (ERT) users & 
nonusers
Isometric hand grip & 
isokinetic knee extensor 
strength assessed by 
dynamometry. Physical 
function assessed using 6-m 
walk & narrow walk speed, 
repeated chair stands, & 
standing balance.
 e associations between ERT & muscle 
composition & strength were minor 
& did not translate into improved 
physical function. Initiation of ERT for 
preservation of muscle composition & 
function may not be indicated.
Maddalozzo et 
al.45
Non-randomized 
[self-selected HRT and 
non-HRT replaced] post-
menopausal women.
Upper- & lower-body 
peak force by isokinetic 
dynamometry & leg power 
by the Bassey Power Rig.
HRT does not play a role in either 
increasing or maintaining strength, lean 
muscle mass, lower limb power, or the 
attenuation of increases in total body 
or abdominal fat, at least in this group 
of postmenopausal women during the 
initial years of menopause.
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To date, there is still no unanimous consensus 
regarding the e ect of oestrogen on muscle strength. 
 ere is almost the same number of papers supporting 
an e ect of oestrogen on skeletal muscle function as 
there are showing no e ect. Moreover, both positive 
and negative correlations have been reported when 
an e ect was evident. Future work should focus on 
discrete elements of muscle strength and use the 
best and most appropriate models of reproductive 
functioning available; i.e. models that cause the greatest 
magnitude of change in sex hormone concentration 
(e.g. IVF). In addition, future work should aim to 
control as many confounding factors as possible (e.g. 
age, smoking, exercise status etc.). Moreover, there is 
a need to conduct meta-analyses on previous research 
in order to move towards a conclusion on this topic. 
Conclusions
still a number of publications that have used a variety 
of types and brands of OC’s33,63 and HRT’s39,41, which 
can lead to extremely large variation in hormone 
concentration when grouped together and may 
ultimately lead to type II errors27.
 e term “muscle strength” is too ambiguous 
and makes comparing studies and drawing any 
conclusions very di!  cult. In the last decade, over 20 
indices of muscle strength or determinants of muscle 
strength have been investigated (see TABLES 1 and 
2 for exact tests). It would be judicious to perform 
a meta-analysis on each of the main components of 
strength (dynamic, isometric, endurance, power) 
in relation to oestrogen status. It is interesting to 
note that recently several studies have investigated 
the effect of oestrogen on the gene expression 
in uencing muscle strength and hypertrophy37,44, 
indicating a new direction for this type of research.
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